Company / Working Capital
Terns Pharmaceuticals, Inc. Working Capital History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$346.5M
FY2024
5-year range
$68.0M / $346.5M
FY2020-FY2024
Trend
+35.6%
vs FY2023
Sector context
#125 of 214
Health Care
What the data says
At $346M, Terns Pharmaceuticals, Inc.'s working capital ranks #125 of 214 in the Health Care sector. Improved from $277M to $346M over the past 2 years.
Based on SEC 10-K filings.
$346M in FY2024 with a 3-year CAGR of +29.3%.
Improved from $277M to $346M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +29.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#125 of 214 in Health CareTop 58% of 214This company $346.5M Sector average $955.5M
▼
-63.7% below sector average
Key checks
Key Insights
- 3-year CAGR of +29.3%, indicating consistent growth.
- In FY2024, working capital increased 35.6% year-over-year.
- Ranks #125 out of 214 companies in the Health Care sector.
- Lowest working capital in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $346.5M | +35.6% |
| FY2023 | $255.5M | -7.7% |
| FY2022 | $276.7M | +72.8% |
| FY2021 | $160.1M | +135.3% |
| FY2020 | $68.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026